开发和验证风险评分,预测心力衰竭患者不服药的风险评分
Tomoaki Ishida1,2, Kei Kawada3,4, Kohei Jobu1
1Department of Pharmacy, Kochi Medical School Hospital, Nankoku, Kochi 783-0043, Japan.
Biological & pharmaceutical bulletin
|February 18, 2026
概括
一个新的风险评分识别了可能在出院后不坚持药物治疗的心力衰竭患者. 高分数预示着更高的死亡率,使得针对性干预能够更好地管理心力衰竭.
科学领域:
- 心脏病学 心脏病学
- 临床医学 临床医学
- 医疗保健服务研究 医疗服务研究
背景情况:
- 药物不服药是心力衰竭 (HF) 管理中的一个重要问题.
- 识别患有不服药高风险的患者对于改善治疗结果至关重要.
研究的目的:
- 开发和验证临床上适用的风险评分,用于预测在入院时不补偿性心力衰竭患者的药物不服药.
主要方法:
- 一项前性,多中心的队列研究招募了795名HF患者.
- 后勤回归确定了不遵守的预测因素;获得了风险得分.
- 模型性能是使用接收器操作特征曲线 (AUC) 下的面积来评估的.
主要成果:
- 由于不服药导致的住院治疗发生在6.4%的患者.
- 预测因素包括痴呆症,男性性别,目前的吸烟,无辅助生活和之前的HF住院治疗.
- 较高的风险得分与2年内所有原因和心血管死亡率的增加相关 (AUC = 0.704).
结论:
- 基于入院的风险评分有效地识别了患有HF患者的药物不服药风险.
- 这个分数可以指导有针对性的干预措施,以改善坚持和长期的HF结果.
- 将其纳入常规护理可能会减少出院后的并发症,并加强多学科规划.
相关概念视频
Heart Failure V: Medical Management
381
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
381
Heart Failure VII: Nursing Interventions
559
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
559
Heart Failure IV: Classification and Diagnostic Evaluation
453
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
453
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.2K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K
Heart Failure VI: Adjunct Therapies
417
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
417
Drug Toxicity: Risk factors
27
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
27


